Home/Investors/Eli Lilly

Eli Lilly

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$156.1B

Focus Areas

6

Top Stage

Commercial

Investment Focus

Oncology Metabolic Disorders Autoimmune Diseases Rare Diseases Cardiometabolic Liver Diseases

Portfolio Companies

Company	Stage	Valuation	Focus
Innovent Biologics	Commercial	$156.1B	Oncology, Metabolic Disorders
Dicerna Pharmaceuticals	Phase 3	—	Rare Diseases, Cardiometabolic

Frequent Co-Investors

Hillhouse Capital1 shared Boyu Capital1 shared Various institutional and public market investors1 shared Novo Nordisk A/S1 shared Roche1 shared Alexion Pharmaceuticals1 shared Capital Group1 shared